LBT to trial diabetic foot ulcer prototype
LBT Innovations, an Australian-listed medical technology company, has signed an agreement with Central Adelaide Local Health Network (CALHN) Vascular and Endovascular Services to trial LBT’s WoundVue prototype device in patients with diabetic foot ulcers.
WoundVue is a handheld portable device that takes 2D and 3D images of chronic wounds to objectively monitor wound healing. The technology behind the device originates from the principles behind LBT’s FDA Cleared APAS platform, where the core machine learning algorithms have been adapted to interpret tissue types and automatically provide surface area, volume and depth measurements.
“Using WoundVue in this trial will provide us with reliable and objective data that will feed into our predictive model for amputations resulting from diabetic foot ulcers,” said Professor Rob Fitridge, Head of Vascular Surgery at CALHN and Lyell McEwin Hospital, and Professor of Vascular Surgery at the University of Adelaide.
“This collaboration is the logical next step having recently completed the proof-of-principle work developing our core algorithms in automatic tissue identification and delivering a prototype device. Development of validated medical devices in a regulated environment takes time. We are excited to collaborate with Professor Fitridge and his team to have the WoundVue prototype device being used in a clinical setting that will allow for further development of our core technology,” said LBT CEO and Managing Director Brent Barnes.
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
